Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 1 / Phase 2	2026-02-24		NCT00378105

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beth Israel Deaconess Medical Center	161
Brigham and Women's Hospital	378
Celgene Corporation	20
Dana-Farber Cancer Institute	324
Massachusetts General Hospital	758
Millennium Pharmaceuticals, Inc.	9

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beth Israel Deaconess Medical Center	Boston	United States	45
Dana-Farber Cancer Institute	Boston	United States	68
Massachusetts General Hospital	Boston	United States	1015